Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.64 |
| ▸ | GUSB | P08236 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252149 | 0.92 | DGAT1 (0.58) | DGAT1GUSBMMP2MMP9MMP8 | |
| SCHEMBL13695119 | 0.88 | DGAT1 (0.69) | DGAT1MMP2MMP9MMP8MMP3 | |
| SCHEMBL1250496 | 0.85 | DGAT1 (0.80) | DGAT1GUSB | |
| SCHEMBL31326547 | 0.85 | DGAT1 (0.83) | DGAT1PDCD1CD274 | |
| SCHEMBL1252030 | 0.85 | DGAT1 (0.83) | DGAT1PDCD1CD274 | |
| SCHEMBL10299677 | 0.81 | DGAT1 (0.83) | DGAT1GUSBMMP2MMP9MMP8 | |
| SCHEMBL1252127 | 0.81 | DGAT1 (0.69) | DGAT1GUSBATRQPCT | |
| SCHEMBL1252922 | 0.79 | DGAT1 (0.72) | DGAT1PDCD1CD274QPCT | |
| SCHEMBL1252216 | 0.79 | DGAT1 (1.00) | DGAT1GUSB | |
| SCHEMBL30385298 | 0.79 | DGAT1 (1.00) | DGAT1GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552441-B1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2016-05-04 | — | — | EP | claimed |
| EP-2552441-A1 | USES OF DGAT1 INHIBITORS | Novartis AG (CH) | 2013-02-06 | — | — | EP | claimed |
| US-20130023495-A1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | US | claimed |
| WO-2011123401-A1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2011-10-06 | — | — | WO | claimed |
| EP-2205595-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | claimed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | claimed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | claimed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | claimed |
| EP-2552441-B1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2016-05-04 | — | — | EP | disclosed |
| US-9061012-B2 | Uses of DGAT1 inhibitors | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | disclosed |
| EP-2205595-B1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013169648-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A DGAT1 INHIBTOR AND A TRIGLYCERIDE LOWERING DRUG | NOVARTIS AG (CH) | 2013-11-14 | — | — | WO | disclosed |
| EP-2552441-A1 | USES OF DGAT1 INHIBITORS | Novartis AG (CH) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023495-A1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | US | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023495-A1 | USES OF DGAT1 INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885GUSB 945/4885MMP2 2569/4885 |
| US-20090186891-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885GUSB 217/4885MMP2 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.